4//SEC Filing
Ryan Jason 4
Accession 0001415889-24-027473
CIK 0001818331other
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 8:21 PM ET
Size
19.4 KB
Accession
0001415889-24-027473
Insider Transaction Report
Form 4
Ryan Jason
Director
Transactions
- Sale
Class A Common Stock
2024-11-20$70.50/sh−4,272$301,185→ 0 total(indirect: By Jason Ryan u/a dtd 11/25/2018) - Gift
Class A Common Stock
2024-11-19−141,356→ 47,000 total(indirect: By Trust) - Sale
Class A Common Stock
2024-11-20$69.84/sh−1,857$129,689→ 4,272 total(indirect: By Trust) - Sale
Class A Common Stock
2024-11-19$70.86/sh−5,952$421,784→ 41,048 total(indirect: By Trust) - Sale
Class A Common Stock
2024-11-19$71.35/sh−24,784$1,768,420→ 16,264 total(indirect: By Trust) - Sale
Class A Common Stock
2024-11-19$72.26/sh−774$55,927→ 15,490 total(indirect: By Trust) - Sale
Class A Common Stock
2024-11-20$68.36/sh−9,361$639,876→ 6,129 total(indirect: By Trust)
Holdings
- 141,356(indirect: By Jason Ryan 2024 GRAT)
Class A Common Stock
- 130
Class A Common Stock
Footnotes (7)
- [F1]On November 19, 2024, the reporting person transferred 141,356 shares of GeneDx Holdings Corp. Class A common stock from the reporting person's indirect holdings to the Jason Ryan 2024 GRAT (the "GRAT") for no consideration. The reporting person is the trustee of the GRAT, and the reporting person is the sole annuitant of the grantor retained annuity trust. The reporting person remains the beneficial owner of the securities held by the grantor retained annuity trust.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.026 to $71.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.04 to $72.0302 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.12 to $72.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.01 to $68.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.22 to $70.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.22 to $70.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
GeneDx Holdings Corp.
CIK 0001818331
Entity typeother
Related Parties
1- filerCIK 0001585017
Filing Metadata
- Form type
- 4
- Filed
- Nov 20, 7:00 PM ET
- Accepted
- Nov 21, 8:21 PM ET
- Size
- 19.4 KB